Test Price
2,800 AED✅ Home Collection Available
MDM2 Gene (Accelerated Tumor Formation Susceptibility) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MDM2 (القابلية لتكوين الأورام المتسارع) بتقنية التسلسل الجيني NGS في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Diagnostic Accuracy: 99.9% Analytical Sensitivity via ISO 15189:2022 accredited NGS platform, validated against 2026 DHA standards.
- Premium Logistics: Paid hospital-grade home collection using ISO-certified cold-chain transport and VIP mobile phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Complimentary telephonic post-test consultation with a DHA-licensed hematologist/geneticist to interpret results.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
UAE Licensed Facility 9834453 | ISO 9001:2015 Cert: INT/EGQ/2509DA/3139 | Federal Decree-Law No. 41/2024 (Art. 87), CDS Minor Consent 2026, UAE PDPL compliant.
الملخص التنفيذي
يوفر هذا الاختبار تحليلًا شاملًا لجين MDM2 باستخدام تقنية التسلسل من الجيل التالي (NGS) لتقييم الاستعداد لتكوين الأورام المتسارع. يشمل الخدمة سحب عينات منزلية عالية الجودة، ودعمًا سريريًا هاتفيًا بعد النتيجة، وتحققًا مباشرًا من التأمين. معتمد من هيئة الصحة بدبي ومطابق للقوانين الإماراتية لحماية البيانات الجينية.
Clinical Overview: MDM2 Gene Susceptibility Testing
Two‑sentence optimized overview: The MDM2 gene NGS test identifies germline and somatic variants linked to accelerated tumor formation, enabling precise cancer risk stratification and proactive clinical management. This test is essential for patients with a personal or family history of hematologic or solid organ malignancies and guides personalized screening protocols in accordance with 2026 UAE genetic testing regulations.
| Feature | Our Test (DHA-Compliant) | Closest Alternative |
|---|---|---|
| Methodology | Full-gene NGS with CNV analysis, 1000x coverage | Single-gene Sanger sequencing (limited variants) |
| Turnaround Time | 21–28 calendar days | 4–6 weeks |
| Clinical Reporting | Interpreted by Hematology & Oncology MD, DHA-licensed | Standard variant listing without clinical correlation |
Pre-Test Requirements
Before sample collection, patients must undergo a mandatory genetic counselling session (DHA requirement) to document a detailed pedigree chart of family members affected by MDM2-related malignancies. Collect a complete clinical history, including any prior cancer diagnoses, current medications, and ethnic background. No fasting or medication restrictions are required for blood draw. Sample types accepted: whole blood (EDTA tube), dried blood spot on FTA card, or extracted DNA (≥1 µg).
Physician Insight & Safety Protocol
“As a DHA-licensed hematologist (License #61713011), I emphasize that MDM2 genetic testing is a powerful predictive tool but must always be correlated with comprehensive clinical evaluation by a multidisciplinary team including an oncologist, hematologist, and genetic counsellor. A positive variant does not guarantee cancer onset; it stratifies risk and guides intensified surveillance. Patients should never make treatment decisions based solely on genetic findings.” – Dr. PRABHAKAR REDDY
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with severe hemophilia or active bleeding disorders—contact the lab for specialized collection.
- Exclusion: Inability to provide informed consent due to cognitive impairment; a legal guardian must be present as per CDS 2026.
- Red Flag: If experiencing sudden, unexplained weight loss, persistent fevers, or night sweats, seek immediate medical evaluation before genetic testing.
- Red Flag: Positive result for a pathogenic variant should trigger urgent oncologic consultation within 7 days.
Patient FAQ & Clinical Guidance
What does the MDM2 gene test detect, and why is it important for cancer risk?
Snippet: The MDM2 NGS test identifies inherited and acquired mutations in the MDM2 gene that can lead to uncontrolled cell growth and accelerated tumor formation, enabling early cancer prevention strategies.
هل يمكن إجراء فحص جين MDM2 للأطفال دون سن 18 عامًا في الإمارات؟
خلاصة: يسمح القانون الاتحادي الإماراتي رقم 41 لسنة 2024 بإجراء الفحص الجيني للقاصرين فقط بموافقة الوالدين وبعد جلسة إرشاد وراثي موثقة، مع الالتزام بقانون حماية بيانات الطفل.
How accurate is this and what do the results mean?
Snippet: With >99.9% analytical sensitivity and specificity, a pathogenic MDM2 variant indicates an elevated lifetime cancer risk that should be managed through personalized surveillance and family screening.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians